Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ValiRx PLC tees up £4mln through convertible issue

The agreement will see Bracknor subscribe for the convertible loan notes in eight equal tranches of £0.5mln
ValiRx PLC tees up £4mln through convertible issue
ValiRx has one drug, VAL201, going through phase I/II trials

Cancer drug developer ValiRx Plc (LON:VAL) has set up a £4mln convertible loan facility with agreement with Bracknor Fund Ltd a private mutual fund incorporated in the British Virgin Islands.

The agreement will see Bracknor subscribe for the convertible loan notes in eight equal tranches of £0.5 million each. As part of the agreement, the Company has agreed to issue warrants to Bracknor. 

ValiRx has one drug, VAL201, going through phase I/II trials, and has made an application to start a second for another cancer treatment, VAL401.

PhilW.jpg
Why Invest In ValiRx Plc? Read More Here

Register here to be notified of future VAL Company articles
View full VAL profile

ValiRx Plc Timeline

Big Picture
May 19 2016

Related Articles

Cancer
March 31 2016
This broad coverage protects the company's lead immunotherapy, ImMucin
knee_5672a90cad559.jpg
December 17 2015
Put simply, Tissue Regenix takes a tendon or cartilage – either from a human or from a pig – treats it and uses it to replace damaged tissue within the body.
Astrazeneca-laboratory-testing_opt.jpg
October 20 2015
The highly regarded biotech entrepreneur David Evans, who is Scancell’s chairman, said given the strength of the clinical data from SCIB1 and the pipeline of potential products, further investment is warranted and in his words “could add significant value to the company”.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.